An Old Dog with a New Trick… Ellodi’s APT-1011 Promises EoE Patients a Convenient and Potent Treatment Alternative
Moreover, Dupixent continues to enjoy a unique position as the only advanced treatment for EoE.
- Moreover, Dupixent continues to enjoy a unique position as the only advanced treatment for EoE.
- Consequently, an unlikely candidate has emerged as the next significant advancement in EoE, potentially landing the coveted second-to-market position.
- APT-1011, a reformulation of the commonly used EoE treatment fluticasone, achieved significant improvements in both histologic and symptomatic endpoints.
- Speaking with physicians in depth, Spherix explored the benefits and implications of APT-1011 when compared to the gold standard EoE treatment, Dupixent.